Solid composition

Abstract

To provide a solid composition containing ibuprofen, the change in properties of which is suppressed. The present invention relates to a composition comprising: (A) ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and its salts A solid composition comprising, except for a solid composition comprising levocetirizine or loratadine.

Description

[Technical field]

[0001] The present invention broadly relates to a solid composition comprising ibuprofen, at least one member selected from the group consisting of tipepidine and its salts, and at least one member selected from the group consisting of tranexamic acid and its salts. [Background technology]

[0002] Ibuprofen is widely used as a nonsteroidal antipyretic analgesic. However, a solid composition containing ibuprofen may undergo changes in properties over time, such as discoloration, melting, separation, solidification, wetting, and aggregation, due to the incorporation of other ingredients, and therefore, studies have been conducted on the inhibition of such changes in properties.

[0003] For example, Patent Document 1 discloses a pharmaceutical composition containing ibuprofen, diphenhydramine, and dextromethorphan, as well as tranexamic acid.

[0004] Patent Document 2 discloses a pharmaceutical composition containing ibuprofen, dextromethorphan, and guaifenesin, as well as tranexamic acid.

[0005] Patent Document 3 discloses a pharmaceutical composition containing ibuprofen, levocetirizine, and at least one selected from the group consisting of carbocysteine, ambroxol, tranexamic acid, glycyrrhizinic acid, tipepidine, dextromethorphan, bromhexine, dimemorfan, and methylephedrine.

[0006] Patent Document 4 discloses a solid composition containing ibuprofen, loratadine, and at least one selected from the group consisting of carbocysteine, ambroxol, bromhexine, tranexamic acid, glycyrrhizinic acid, tipepidine, and dextromethorphan. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Patent Publication No. 2021-075528 [Patent Document 2] Patent Publication No. 2021-075530 [Patent Document 3] Patent Publication No. 2022-008041 [Patent Document 4] JP 2020-158487 A Summary of the Invention [Problem to be solved by the invention]

[0008] The solid composition containing ibuprofen has room for improvement in terms of changes in properties over time. The present invention aims to provide a solid composition containing ibuprofen in which changes in properties are suppressed. [Means for solving the problem]

[0009] The present inventors have found that when ibuprofen is combined with at least one selected from the group consisting of tipepidine and its salts, a significant change in properties occurs. Furthermore, they have found that the change in properties can be suppressed by combining at least one selected from the group consisting of tranexamic acid and its salts, and have completed the present invention.

[0010] That is, the present embodiment includes the following aspects. [1] A solid composition comprising: (A) ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and its salts A solid composition comprising, except for a solid composition comprising levocetirizine or loratadine. [2] The solid composition according to [1], wherein a mass ratio of the total amount of component (A) to component (B) is 1:1 to 16:1 ((A):(B)). [3] The solid composition according to [1] or [2], comprising a crystal of ibuprofen and tranexamic acid. [4] The solid composition according to [3], wherein the molar ratio of ibuprofen to tranexamic acid in the crystals is 1:1. [5] An agent for inhibiting property changes in a solid composition comprising at least one member selected from the group consisting of tranexamic acid and its salts, (I) ibuprofen, and (II) at least one member selected from the group consisting of tipepidine and its salts. Effect of the Invention

[0011] According to the present invention, it is possible to provide a solid composition containing ibuprofen, in which changes in properties are suppressed. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows the results of differential scanning calorimetry (DSC) of the crystals composed of ibuprofen and tranexamic acid obtained in Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hereinafter, an embodiment of the present invention (hereinafter referred to as "the present embodiment") will be described, but the scope of the present invention is not limited to the following embodiment. In this embodiment, the composition may contain each component alone or in combination of two or more kinds. In this specification, the symbol "to" indicating a numerical range means "at least" or "at most", and includes both of the numerical values ​​at both ends.

[0014] (solid composition) In a first embodiment, the composition comprises the following ingredients: (A) ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and its salts A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine. is provided. The solid composition is in particular a solid pharmaceutical composition.

[0015] Each component contained in the solid composition according to this embodiment may be contained in the form of a pharmacologically acceptable salt, or may be contained as a complex with other components. That is, the solid composition according to this embodiment may contain salts of each component, not only for components (B) to (C), but also for component (A) and other components. The term "pharmacologically acceptable salt" includes, for example, salts with medicamentously acceptable bases and acids. Non-limiting specific examples of pharmacologically acceptable salts include addition salts of inorganic acids (hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.), addition salts of organic acids (p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carboxylic acids, succinic acid, citric acid, benzoic acid, acetic acid, etc.), addition salts of inorganic bases (ammonium hydroxide or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, etc.), and addition salts of amino acids, etc. The pharmacologically acceptable salt may be a hydrate salt or an anhydrous salt.

[0016] In this embodiment, since the solid composition contains the above-mentioned component (C) in addition to at least one selected from the group consisting of ibuprofen, and tipepidine and its salts, changes in properties of the solid composition, particularly changes in properties over time, are suppressed.

[0017] In this specification, "change in property" means a change in nature and / or state, including at least aggregation, solidification, discoloration, moisture absorption, separation, and liquefaction. Therefore, the solid composition of this embodiment may be suppressed from any of aggregation, discoloration, moisture absorption, separation, and liquefaction that occur over time. In addition, "change in property is suppressed" means that the property change is unlikely to occur, but may be suppressed, for example, when compared with a solid composition that does not contain the above-mentioned component (C).

[0018] The solid composition of the present embodiment may be suppressed from changing in properties under high temperature conditions. The high temperature conditions may be, for example, 30 to 100°C, or 40 to 90°C.

[0019] The period during which the property change is suppressed in the solid composition of this embodiment is not particularly limited, and may be, for example, 12 hours or more, 18 hours or more, 24 hours or more, one week or more, or two weeks or more.

[0020] It should be noted that the solid composition of this embodiment excludes "a solid composition containing levocetirizine or loratadine."

[0021] Here, "levocetirizine" means a compound having the chemical formula C 21 H 25 It is a compound represented by ClN2O3. Levocetirizine is an optical isomer of cetirizine obtained by optical resolution of only the R-enantiomer, which has stronger physiological activity, and has a CAS registration number of 130018-77-8. In addition, the solid composition of this embodiment excludes a solid composition containing a salt of levocetirizine. The salt of levocetirizine is not particularly limited as long as it is a pharmacologically acceptable salt, and examples thereof include salts of inorganic acids such as hydrochloride, hydrobromide, and phosphate, and salts of organic acids such as acetate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, and carbonate, and the like, and particularly hydrochloride.

[0022] Here, "loratadine" means a compound having the chemical formula C 22 H 23 The compound is represented by ClN2O2 and its CAS registration number is 79794-75-5.

[0023] In addition, the solid composition of this embodiment excludes the solid compositions disclosed in JP 2022-008041 A and JP 2020-158487 A. The solid composition disclosed in JP 2022-008041 A is a pharmaceutical composition in which the decrease in the content of levocetirizine or a salt thereof over time is suppressed even when it contains ibuprofen and levocetirizine or a salt thereof, and the solid composition disclosed in JP 2020-158487 A is a solid composition in which the decrease in the content of loratadine over time is suppressed even when it contains ibuprofen and loratadine, but the solid composition of this embodiment is a solid composition containing ibuprofen in which the property change that may occur by blending at least one selected from the group consisting of tipepidine and its salts with ibuprofen is suppressed.

[0024] (A) Ibuprofen As used herein, "ibuprofen" refers to the compound having the CAS Registry Number 15687-27-1 and C 13 H 18 It is a compound represented by the chemical formula O2 (molecular weight: 206.29 g / mol). Ibuprofen is used as an active ingredient in anti-inflammatory, analgesic, and antipyretic drugs. There are no particular limitations on the salt of ibuprofen as long as it is pharmacologically acceptable.

[0025] The amount of ibuprofen is appropriately adjusted depending on the purpose of ibuprofen in the solid composition, symptoms, age, weight, sex, etc. of the subject to be administered. For example, when ibuprofen is incorporated as a nonsteroidal anti-inflammatory drug, the amount of ibuprofen administered to an adult per day can be adjusted within the range of, for example, 30 mg to 2000 mg, preferably 100 mg to 1000 mg, and more preferably 200 mg to 600 mg. In this embodiment, "adult" means males and females aged 15 years or older. However, the solid composition according to this embodiment is not limited to that for adults, and may be that for children under 15 years old. When administered by children, the amount can be reduced to 1 / 2 or 2 / 3 of the amount administered by adults per day depending on each age group. The same applies to ingredients other than ibuprofen.

[0026] The above dosage is an example, and the ibuprofen content per solid composition administered per day is, for example, about 1% by mass to about 70% by mass, preferably about 5% by mass to about 50% by mass, and more preferably about 10% by mass to about 30% by mass.

[0027] In one embodiment, the content of ibuprofen in the composition to be administered daily is 1 to 70% by mass, preferably 5 to 50% by mass, and more preferably 10 to 30% by mass.

[0028] The weight and dosage of the above solid composition are the dosage per day (daily amount), but the same amount may be administered to the subject once or multiple times a day, for example, twice or three times, preferably three times. The same applies to ingredients other than ibuprofen. In addition, since each dosage is the total amount, the content of each ingredient contained in the solid composition may vary depending on the dosage per time and the dosage form of the solid composition.

[0029] In a specific embodiment, the solid composition is a tablet, and the dosage is the amount of the ingredient contained in 3, 6, or 9 tablets, preferably the amount of the ingredient contained in 9 tablets. In this embodiment, the dosage for an adult (15 years of age or older) is 3 tablets, and the dosage is 2, 3, or 4 tablets, preferably 3 tablets.

[0030] References herein to the amount of ibuprofen may be in terms of the total amount of tranexamic acid and crystallized and non-crystallized ibuprofen.

[0031] In one embodiment, the solid composition comprises tranexamic acid and crystallized ibuprofen and tranexamic acid and non-crystallized ibuprofen.

[0032] In one embodiment, the ibuprofen contained in the solid composition is 90% by weight or more, for example 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% by weight, crystallized.

[0033] In one embodiment, the content of tranexamic acid and uncrystallized ibuprofen in the solid composition is, for example, 10% by weight or less, 8% by weight or less, 5% by weight or less, 3% by weight or less, 1% by weight or less, or 0.1% by weight or less, based on the total amount of ibuprofen.

[0034] (B) at least one selected from the group consisting of tipepidine and its salts As used herein, "tipepidine" refers to the compound having the CAS Registry Number 5169-78-8 and C 15 H 17 It is a compound represented by the chemical formula NS2 (molecular weight: 275.43 g / mol). The salt of tipepidine is not particularly limited as long as it is pharmacologically acceptable, and includes tipepidine hibenzate and tipepidine citrate. The following amounts and contents of at least one selected from the group consisting of tipepidine and its salts are amounts and contents of tipepidine and its salts, respectively, but it is preferable that the total amount and content of tipepidine and its salts are within the ranges of amounts and contents described below.

[0035] The amount of at least one component (B) selected from the group consisting of tipepidine and its salts is appropriately adjusted depending on the use of the solid composition, the required level of antitussive and expectorant effect, the required level of stability, and the symptoms, age, weight, sex, etc. of the subject to be administered.

[0036] The amount of at least one selected from the group consisting of tipepidine and its salts may vary depending on the amount of ibuprofen, etc. For example, the mass ratio ((A):(B)) of the total amount of component (A) to component (B) in the solid composition according to this embodiment is preferably 1:1 to 16:1, more preferably 1:1 to 14:1, and even more preferably 1:1 to 10:1 in the solid composition administered per day. By including at least one selected from the group consisting of tipepidine and its salts in the above range relative to ibuprofen, the property change of the solid composition tends to be more suppressed.

[0037] The amount of at least one selected from the group consisting of tipepidine and salts thereof can be adjusted, for example, in the range of 5 mg to 140 mg, more preferably 16 mg to 100 mg per day.

[0038] (C) at least one selected from the group consisting of tranexamic acid and its salts As used herein, "tranexamic acid" refers to the compound having the CAS Registry Number 1197-18-8 and a C 15 NO2 (molecular weight: 157.21 g / mol). Tranexamic acid is used as an active ingredient of anti-inflammatory drugs and the like. There are no particular limitations on the salt of tranexamic acid as long as it is pharmacologically acceptable. The amount and content of at least one selected from the group consisting of tranexamic acid and its salts described below are the amounts and contents of tranexamic acid and tranexamic acid salts, respectively, but it is preferable that the total amount and content of tranexamic acid and tranexamic acid salts is within the range of the amount and content described below.

[0039] The amount of at least one selected from the group consisting of tranexamic acid and its salts is appropriately adjusted depending on the use of at least one selected from the group consisting of tranexamic acid and its salts in the composition. When at least one selected from the group consisting of tranexamic acid and its salts is added for the purpose of improving the property changes or other properties of ibuprofen, the amount of at least one selected from the group consisting of tranexamic acid and its salts varies depending on the amount of ibuprofen, etc., but for example, the amount per day is in the range of 10 mg to 3000 mg, preferably 100 mg to 1500 mg, more preferably 400 mg to 750 mg.

[0040] The content of at least one selected from the group consisting of tranexamic acid and salts thereof in the composition administered daily is 1% by mass to 70% by mass, preferably 5% by mass to 50% by mass, and more preferably 10% by mass to 30% by mass.

[0041] The amount of at least one selected from the group consisting of tranexamic acid and its salts contained in the composition administered daily is, for example, 0.5 to 3.5 parts by mass, preferably 0.6 to 3.0 parts by mass, and more preferably 0.7 to 2.2 parts by mass per part by mass of ibuprofen.

[0042] The description in this specification of the amount of at least one selected from the group consisting of tranexamic acid and salts thereof may refer to the total amount of at least one selected from the group consisting of crystallized tranexamic acid and non-crystallized tranexamic acid and salts thereof.

[0043] In one embodiment, the solid composition comprises ibuprofen and at least one member selected from the group consisting of crystallized tranexamic acid and non-crystallized tranexamic acid and salts thereof.

[0044] In one embodiment, the content of at least one selected from the group consisting of ibuprofen and non-crystallized tranexamic acid and its salts in the solid composition may be, for example, 0 to 50 mass%, 1 to 40 mass%, 2 to 30 mass%, or 2 to 20 mass% relative to the total amount of tranexamic acid and its salts. The content of at least one selected from the group consisting of ibuprofen and non-crystallized tranexamic acid and its salts in the solid composition may be, for example, 8 mass% or less, 5 mass% or less, 3 mass% or less, 1 mass% or less, or 0.1 mass% or less, within the above range, relative to the total amount of tranexamic acid and its salts.

[0045] When ibuprofen and tranexamic acid are present as crystals in the composition, the ibuprofen and tranexamic acid may be present in the crystal in a molar ratio of 1:1. In addition, the ibuprofen and tranexamic acid may form a crystal unit cell of four molecules each.

[0046] In the crystal, hydrogen bonds may be formed between the carboxylic acid group of ibuprofen and the carboxylic acid group of tranexamic acid, and between the carboxylic acid group of ibuprofen and the amino group of tranexamic acid.

[0047] The crystals may have an endothermic peak at about 180° C. in differential scanning calorimetry (DSC). The vicinity of 180° C. may be, for example, in the range of 180° C.±20° C. or in the range of 180° C.±10° C. In addition, in the DSC of the crystals, the heat of fusion peak at about 75° C., which is characteristic of ibuprofen, may disappear.

[0048] The crystal may have, for example, the crystal structure shown in FIG. 1 of JP 2022-70674 A and may have the X-ray diffraction pattern shown in FIG. 2 of the same publication. The crystal may have seven main peaks (2θ=6.3, 8.4, 16.2, 18.5, 19.1, 21.1, 25.6±0.5°) in the X-ray diffraction pattern.

[0049] Crystals consisting of ibuprofen and tranexamic acid can be produced, for example, by the method described in JP 2022-70674 A. Two representative production methods described in the publication are described below.

[0050] A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of: The method includes: (1) forming a flowable fluid of ibuprofen by adding a solvent or by heating; (2) mixing the resulting flowable fluid of ibuprofen with tranexamic acid; and (3) forming crystals from the resulting mixture.

[0051] A method for producing a crystal of ibuprofen and tranexamic acid, comprising the steps of: A method comprising: (1) obtaining a free-flowing fluid of tranexamic acid; (2) mixing the free-flowing fluid of tranexamic acid with ibuprofen, or with a free-flowing fluid of ibuprofen obtained by adding a solvent or by heating; and (3) forming crystals from the mixture.

[0052] (Other Ingredients) The solid composition according to the present embodiment may contain ingredients other than those mentioned above depending on its application. When the solid composition is used for the purpose of relieving cold symptoms such as runny nose, stuffy nose, sneezing, sore throat, cough, phlegm, chills, fever, headache, joint pain, muscle pain, etc., in addition to bromhexine, meloxicam, and acetaminophen, active ingredients such as antipyretic analgesics, particularly nonsteroidal anti-inflammatory drugs (NSAIDs) other than ibuprofen, and other pharmacologically acceptable ingredients may be blended.

[0053] Nonsteroidal anti-inflammatory drugs are broadly classified into nonselective COX-2 inhibitors such as diclofenac, loxoprofen, zaltoprofen, pranoprofen, oxaprozin, tiaprofenic acid, naproxen, lornoxicam, ampiroxicam, piroxicam, nabumetone, indomethacin, sulindac, mofezolac, and mefenamic acid, and selective COX-2 inhibitors such as meloxicam, etodolac, and celecoxib. Meloxicam may be incorporated into the composition as a nonsteroidal anti-inflammatory drug. The nonsteroidal anti-inflammatory drug is preferably a nonselective COX-2 inhibitor. The nonsteroidal anti-inflammatory drug may be in the form of a salt.

[0054] Other pharmacologically acceptable ingredients may be added, such as antihistamines, antipyretics, antitussives, expectorants, anti-inflammatory drugs, central nervous system stimulants, vitamins, anticholinergics, and antiplasmin agents, which are added to general cold medicines, antipyretics, and rhinitis medicines.

[0055] For example, antihistamines include isopendyl hydrochloride, difeterol hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fenethazine hydrochloride, methdilazine hydrochloride, dl-chlorpheniramine maleate, d-chlorpheniramine maleate, carbinoxamine diphenyldisulfonate, diphenylpyraline hydrochloride, diphenylpyraline theoclate, diphenhydramine hydrochloride, diphenhydramine salicylate, alimemazine tartrate, diphenhydramine tannate, triprolidine hydrochloride hydrate, mebhydroline napadisilate, promethazine methylenedisalicylate, carbinoxamine maleate, difeterol phosphate, clemastine fumarate, mequitazine, and the like.

[0056] Examples of antipyretic analgesics other than nonsteroidal anti-inflammatory drugs include aspirin, acetaminophen, ethenzamide, sazapirin, salicylamide, lactylphenetidine, isopropylantipyrine, etc. Acetaminophen may be incorporated into the composition as an antipyretic analgesic.

[0057] Antitussive and expectorant drugs include noscapine hydrochloride, dextromethorphan hydrobromide hydrate, bromhexine, dihydrocodeine phosphate, dl-methylephedrine hydrochloride, dl-methylephedrine saccharin salt, pseudoephedrine hydrochloride, ambroxol hydrochloride, and L-carbocysteine.

[0058] Anti-inflammatory drugs include glycyrrhizinic acid and its derivatives and salts thereof (eg, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, etc.).

[0059] Examples of central nervous system stimulants include caffeine, anhydrous caffeine, and the like.

[0060] Vitamin preparations include vitamin B1 and its derivatives and their salts (e.g., benfotiamine), vitamin B2 and its derivatives and their salts (e.g., riboflavin), vitamin C and its derivatives and their salts (e.g., ascorbic acid), hesperidin and its derivatives and their salts, etc.

[0061] Anticholinergic agents include scopolamine hydrobromide, Datura extract, methylscopolamine bromide, methyl-l-hyoscyamine bromide, pirenzepine hydrochloride, butylscopolamine bromide, belladonna alkaloids, belladonna extract, belladonna total alkaloids, isopropamide iodide, diphenylpiperidinomethyldioxolane iodide, Scolytsum extract, Scolytsum root, and Scolytsum root total alkaloid citrate.

[0062] The solid composition according to the present embodiment may further contain a formulation additive, if necessary. The formulation additive may be a pharma- ceutically acceptable carrier, such as an excipient, a binder, a disintegrant, a disintegration aid, a glossing agent, a foaming agent, a moisture-proofing agent, a surfactant, a stabilizer, an antioxidant, a filler, a sweetener, a flavoring agent, a refreshing agent, a flavoring, a coloring agent, a base, a coating agent, a sugar-coating agent, a plasticizer, a dispersant, an antifoaming agent, a fluidizing agent, and a flavoring agent or flavoring agent, and the formulation additives that can be used in conventionally known solid formulations may be used for the above-mentioned purpose.

[0063] Examples of excipients include candy powder, gum arabic, powdered gum arabic, cacao butter, caramel, sodium carboxymethyl starch, hydrated silicon dioxide, anhydrous amorphous silicon oxide, xylitol, magnesium aluminosilicate, calcium silicate, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, crystalline cellulose-carmellose sodium, crystalline cellulose (fine particles), crystalline cellulose (granules), powdered cellulose, synthetic aluminum silicate, synthetic aluminum silicate-hydroxypropyl starch-crystalline cellulose, wheat starch, rice flour, rice starch, heavy anhydrous silicic acid, refined white sugar, refined white sugar spherical granules, gelatin, D-sorbitol, calcium carbonate, magnesium carbonate, precipitated calcium carbonate, and low-substituted hydroxypropyl cellulose. , dextrin, corn starch, corn starch granules, trehalose, lactose hydrate, lactose granules, white sugar, potato starch, hydroxypropyl starch, partially gelatinized starch, powdered sugar, powdered candy, powdered reduced maltose syrup, powdered cellulose, pectin, polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 60, maltitol, D-mannitol, magnesium aluminum metasilicate, calcium sulfate, erythritol, glucose, fructose, etc.

[0064] Examples of binders include gum arabic, powdered gum arabic, plum flour, gelatin, shellac, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyvinyl alcohol (fully saponified), polyvinyl alcohol (partially saponified), methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, butyl methacrylate-methyl methacrylate copolymer, methylcellulose, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, and the like.

[0065] Examples of disintegrants include sodium carboxymethyl starch, carmellose, carmellose calcium, croscarmellose sodium, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, hydroxypropyl starch, partially pregelatinized starch, and the like.

[0066] Examples of disintegration aids include sodium carboxymethyl starch, carmellose, carmellose calcium, croscarmellose sodium, light anhydrous silicic acid, crystalline cellulose, sodium bicarbonate, precipitated calcium carbonate, lactose hydrate, hydroxypropyl starch, polysorbate 40, polysorbate 60, polysorbate 80, macrogol 1500, macrogol 4000, and the like.

[0067] Examples of gloss agents include carnauba wax, white beeswax, refined shellac, macrogol 400, macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000NF, and beeswax.

[0068] Examples of the foaming agent include dry sodium carbonate, tartaric acid, potassium hydrogen tartrate, sodium hydrogen carbonate, anhydrous citric acid, and the like.

[0069] Examples of moisture-proofing agents include ethyl cellulose, olive oil, dried aluminum hydroxide gel, glycerin, magnesium silicate, light anhydrous silicic acid, hardened oil, synthetic aluminum silicate, sucrose fatty acid esters, stearic acid, magnesium stearate, refined shellac, refined white sugar, talc, neutral anhydrous sodium sulfate, precipitated calcium carbonate, a mixture of fumaric acid, stearic acid, polyvinyl acetal diethylaminoacetate, and hydroxypropyl methylcellulose 2910, polyvinyl acetal diethylaminoacetate, and magnesium aluminometasilicate.

[0070] Examples of surfactants include sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbit beeswax, polyoxyethylene nonylphenyl ether, polyoxyethylene (20) polyoxypropylene (20) glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (10) polyoxypropylene (4) cetyl ether, polysorbate 20, polysorbate 60, polysorbate 80, macrogol 400, sorbitan monooleate, glyceryl monostearate, sorbitan monostearate, sorbitan monolaurate, and sodium lauryl sulfate.

[0071] Examples of the stabilizer include adipic acid, L-aspartic acid, sodium L-aspartate, DL-alanine, L-alanine, L-arginine, L-arginine hydrochloride, sodium alginate, propylene glycol alginate, benzoic acid, sodium benzoate, ethylenediamine, calcium disodium edetate, sodium edetate, tetrasodium edetate, tetrasodium edetate tetrahydrate, zinc chloride, ammonium chloride, calcium chloride hydrate, cetylpyridinium chloride, salt Ferric chloride, sodium chloride, magnesium chloride, cysteine ​​hydrochloride, L-histidine hydrochloride, cocoa butter, carboxyvinyl polymer, carmellose calcium, carmellose sodium, dried sodium carbonate, glycine, glycerin, glycerin fatty acid ester, calcium gluconate hydrate, sodium gluconate, magnesium gluconate, potassium L-glutamate, sodium L-glutamate, L-lysine glutamate, light anhydrous silicic acid, crystalline sodium dihydrogen phosphate, chondroitin Sodium sulfate, zinc oxide, L-cystine, L-cysteine, tartaric acid, sucrose fatty acid esters, stearic acid, refined gelatin, refined soy lecithin, gelatin, gelatin hydrolysate, sorbitan fatty acid esters, taurine, talc, calcium carbonate, potassium bicarbonate, sodium bicarbonate, sodium carbonate hydrate, magnesium carbonate, natural vitamin E, tocopherol, tocopherol acetate, lactose, concentrated glycerin, povidone, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene stearate Tearyl ether, polyoxyethylene cetyl ether, polyoxyethylene nonylphenyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (196) polyoxypropylene (67) glycol, polyoxyethylene coconut oil fatty glyceryl (7E.O.), polysorbate 20, polysorbate 60, polysorbate 80, polyvinyl alcohol (partially saponified), macrogol 300, macrogol 400, macrogol 4000, anhydrous citric acid, anhydrous sodium citrate, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, magnesium aluminometasilicate, methylcellulose, l-menthol, glycerin monostearate, medicinal charcoal, magnesium sulfate hydrate, DL-malic acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, calcium dihydrogen phosphate hydrate, L-leucine, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, etc.

[0072] Examples of antioxidants include ascorbic acid, L-ascorbic acid stearate, citric acid hydrate, soybean lecithin, natural vitamin E, natural vitamin E, tocopherol, tocopherol acetate, ascorbic acid palmitate, sodium pyrosulfite, etc. In the case of a solid composition containing acetaminophen, it is preferable not to incorporate tocopherols as antioxidants or stabilizers.

[0073] Examples of the filler include RSS No.1 raw rubber, starch acrylate 1000, hydrated silicon dioxide, titanium oxide, calcium hydrogen phosphate, and the like.

[0074] Examples of sweeteners include aspartame, acesulfame potassium, amacha, amacha powder, reduced maltose syrup, licorice, licorice extract, licorice powder, xylitol, dipotassium glycyrrhizinate, disodium glycyrrhizinate, saccharin, sodium saccharin hydrate, sucralose, stevia extract, purified stevia extract, refined white sugar, fructose, white sugar, maltitol, D-mannitol, and erythritol.

[0075] Examples of flavoring agents include sodium chloride, Phellodendron bark powder, Phellodendron extract, Coptis chinensis, Coptis chinensis powder, orange, orange oil, cacao powder, fructose, caramel, licorice, licorice extract, licorice powder, xylitol, calcium citrate, citric acid hydrate, sodium citrate hydrate, L-glutamic acid, sodium L-glutamate, grapefruit extract, brown sugar, cinnamon powder, cinnamon oil, saccharin, sodium saccharin hydrate, Japanese pepper powder, tartaric acid, D-tartaric acid, potassium hydrogen tartrate, DL-tartaric acid Examples of indigestible ingredients include sodium salt, ginger powder, sucralose, stevia extract, purified stevia extract, Swertia japonica, D-sorbitol, tannic acid, clove oil, tincture of ginger, capsicum, capsicum powder, spruce powder, trehalose hydrate, bittern powder, plum extract, fructooligosaccharides, powdered sugar, peppermint powder, D-mannitol, dl-menthol, l-menthol, menthol powder, ryunou, ryunou powder, green tea powder, DL-malic acid, sodium DL-malate, lemon oil, and rose oil.

[0076] Examples of the cooling agent include fennel oil, d-camphor, dl-camphor, cinnamon oil, peppermint water, peppermint oil, and l-menthol.

[0077] Examples of flavorings include orange flavor, guarana extract, sweet orange, strawberry, brown sugar flavor, strawberry flavor, cherry flavor, banana powder flavor, peach essence, fruit essence, peppermint, melon powder flavor, l-menthol, and peppermint oil.

[0078] Examples of fragrances include fennel powder, fennel oil, ethyl vanillin, d-camphor, dl-camphor, cinnamon powder, cinnamon oil, ginger oil, ginseng powder, spearmint oil, clove oil, turpentine, chili powder, pineapple powder flavor 51357, pineapple powder flavor 59492, peppermint water, peppermint oil, vanilla powder flavor 54286, vanillin, bergamot oil, d-borneol, dl-borneol, dl-menthol, l-menthol, eucalyptus oil, rose water, rose oil, and the like.

[0079] Examples of colorants include yellow iron oxide, yellow ferric oxide, orange essence, brown ferric oxide, carbon black, caramel, β-carotene, licorice extract, gold leaf, black ferric oxide, titanium oxide, ferric oxide, diaz azo yellow, food blue No. 1, food yellow No. 4, food yellow No. 5, food blue No. 2 aluminum lake, food yellow No. 4 aluminum lake, food red No. 2, food red No. 3, food red No. 102, ferric oxide-glycerin suspension, sodium copper chlorophyllin, copper chlorophyll, phenol red, malachite green, methylene blue, medicinal charcoal, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, green tea powder, and rose oil.

[0080] Bases include: powdered acacia, pregelatinized starch, ethyl cellulose, cacao butter, carnauba wax, carboxyvinyl polymer, carmellose, carmellose sodium, reduced maltose syrup, hydrated silicon dioxide, dried aluminum hydroxide gel, agar, powdered agar, xanthan gum, glycine, glycerin, glycerin fatty acid ester, light anhydrous silicic acid, crystalline cellulose, hardened oil, synthetic aluminum silicate, synthetic sodium magnesium silicate, titanium oxide, tartaric acid, sucrose fatty acid ester, silicon oil, stearic acid, magnesium stearate, gelatin, D-sorbitol, talc, calcium carbonate, corn starch, lactic acid, ethyl lactate, calcium lactate hydrate, lactic acid-glycolic acid copolymer, concentrated glycerin, potato starch, Hydroxypropyl cellulose, hypromellose, pullulan, pectin, povidone, polysorbate 60, polysorbate 80, polyvinyl alcohol (partially saponified), microcrystalline wax, macrogol 200, macrogol 300, macrogol 400, macrogol 1000, macrogol 1500, macrogol 1540, macrogol 4000, macrogol 6000, macrogol 6000NF, macrogol 20000, D-mannitol, glyceryl monostearate, sorbitan monostearate, batyl monostearate, propylene glycol monostearate, polyethylene glycol monostearate, sodium lauryl sulfate, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, etc.

[0081] Examples of coating agents include ethyl acrylate-methyl methacrylate copolymer dispersion, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, gum arabic, powdered gum arabic, ethyl cellulose, ethyl cellulose aqueous dispersion, carnauba wax, carboxyvinyl polymer, gold leaf, silver leaf, triethyl citrate, glycerin, glycerin fatty acid ester, hardened oil, titanium oxide, sucrose fatty acid ester, stearyl alcohol, stearic acid, magnesium stearate, purified gelatin, purified shellac, gelatin, D-sorbitol, talc, calcium carbonate, magnesium carbonate, medium gold leaf, precipitated calcium carbonate, concentrated glycerin, white shellac, hydroxypropyl cellulose, hydroxypropyl methylcellulose acetate succinate, mixture of hydroxypropyl methylcellulose 2910, titanium oxide, and macrogol 400, hypromellose, fumaric acid, stearic acid, polyvinyl acetal diethylaminoacetate, hypromellose, Hydroxypropyl methylcellulose 2910 mixture, pullulan, polysorbate 80, polyvinyl acetal diethylaminoacetate, povidone, polyvinyl alcohol (partially saponified), macrogol 300, macrogol 400, macrogol 600, macrogol 1500, macrogol 1540, macrogol 4000, macrogol 6000, macrogol 6000NF, macrogol 20000, macrogol 35000, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, magnesium aluminum methasilic acid, methyl acrylate-methacrylic acid-methyl methacrylate copolymer, methylcellulose, 2-methyl-5-vinylpyridine methylacrylate-methacrylic acid copolymer, aluminum monostearate, glycerin monostearate, sorbitan monostearate, sorbitan monolaurate, calcium sulfate, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, etc.

[0082] Examples of sugar-coating agents include gum arabic, powdered gum arabic, ethyl cellulose, carnauba wax, carmellose sodium, titanium oxide, stearic acid, polyoxyl 40 stearate, purified gelatin, purified shellac, purified sucrose, gelatin, shellac, talc, precipitated calcium carbonate, white shellac, sucrose, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyvinyl alcohol (partially saponified), macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000NF, calcium hydrogen phosphate hydrate, calcium dihydrogen phosphate hydrate, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, and the like.

[0083] Examples of plasticizers include triethyl citrate, glycerin, glycerin fatty acid esters, D-sorbitol, medium-chain fatty acid triglycerides, triacetin, concentrated glycerin, castor oil, polyoxyethylene hydrogenated castor oil 60, propylene glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polysorbate 80, macrogol 400, macrogol 600, macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000NF, glycerin monostearate, isopropyl linoleate, and liquid paraffin.

[0084] Dispersants include aminoalkyl methacrylate polymer RS, gum arabic, powdered gum arabic, carboxyvinyl polymer, sodium carboxymethyl starch, powdered agar, citric acid hydrate, sodium citrate hydrate, glycerin, glycerin fatty acid ester, magnesium silicate, light aluminum oxide, light anhydrous silicic acid, crystalline cellulose, titanium oxide, sucrose fatty acid ester, stearic acid, magnesium stearate, D-sorbitol, soybean lecithin, and low-substituted hydroxypropyl cellulose. , dextrin, corn starch, lactose hydrate, concentrated glycerin, potato starch, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, povidone, polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, polysorbate 20, polysorbate 60, polysorbate 80, microcrystalline wax, macrogol 300, macrogol 4000, macrogol 6000, macrogol 6000NF, anhydrous sodium citrate, magnesium aluminometasilicate, methylcellulose, glycerin monooleate, sorbitan monooleate, aluminum monostearate, glycerin monostearate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, sodium lauryl sulfate, and the like.

[0085] Antifoaming agents include ethanol, glycerin fatty acid esters, dimethylpolysiloxane (for internal use), dimethylpolysiloxane-silicon dioxide mixtures, sucrose fatty acid esters, silicone antifoaming agents, silicone oil, sorbitan fatty acid esters, polysorbate 80, etc.

[0086] Examples of the fluidizing agent include hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, heavy anhydrous silicic acid, magnesium alumina hydroxide, stearic acid, calcium stearate, magnesium stearate, tricalcium phosphate, talc, magnesium aluminometasilicate, and calcium hydrogen phosphate granules.

[0087] Examples of flavoring agents and fragrances include fennel powder, fennel oil, ethyl vanillin, orange, orange extract, orange essence, orange oil, chamomile oil, caramel, licorice powder, d-camphor, dl-camphor, cinnamon powder, cinnamon oil, citronella oil, sugar flavor, spearmint oil, cherry flavor, clove oil, chili flavor, spruce tincture, spruce oil, pine oil, peppermint oil, vanilla flavor, vanillin, bitter essence, vitabase, Himalayan cedar oil, fruit flavor, Flavor G1, hesperidin peppermint essence, bergamot oil, vermouth flavor, d-borneol, dl-borneol, matcha, mixed flavor, mint flavor, dl-menthol, l-menthol, eucalyptus oil, lavender oil, ryunou, ryunou powder, lemon powder, lemon oil, rose water, rose oil, peppermint oil, etc.

[0088] These components may be contained alone or in combination of two or more.

[0089] (Dosage form) The solid composition of this embodiment may be in the dosage form described in the General Provisions for Preparations of the Japanese Pharmacopoeia, 18th Edition, etc., such as preparations for oral administration (tablets (including orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, etc.), capsules, granules, powders, etc.) and preparations for oral application (including oral tablets, troches, sublingual tablets, buccal tablets, adhesive tablets, gums, etc.). The solid composition of this embodiment is preferably an oral solid composition.

[0090] The dosage form of the solid composition of this embodiment may be, for example, a tablet, a capsule, a pill, a granule, or a fine granule. These solid compositions may be coated with sugar coating or film coating by a known method as necessary. The dosage form of the solid composition is preferably a tablet. Specific examples of tablets include plain tablets, film-coated tablets, and sugar-coated tablets.

[0091] The solid composition of the present embodiment may be once packaged in a bottle, PTP, pouch, stick, or SP package and then stored airtight. These may then be pillow-packaged, or stored in a box or the like. The material used for the pillow packaging is not particularly limited, and may be, for example, a resin film such as a polypropylene film, a polyethylene terephthalate film, or a polyethylene film, or a resin film with aluminum foil attached thereto. If hygroscopicity is a concern, a desiccant or the like may be stored simultaneously in the bottle packaging or pillow packaging.

[0092] The solid composition of the present embodiment may be contained in a packaging container to form a package. The solid composition of the present embodiment may be contained in, for example, an airtight package. By forming the solid composition into a package, for example, the convenience of using the solid composition can be improved. Specifically, the package in the present embodiment is a pharmaceutical product.

[0093] As for the packaging form of the solid preparation, the solid composition may be once packaged and stored airtight in a bottle package, a PTP package (press through package), a pouch package, a stick package, a SP package (strip package), or the like. Furthermore, these may be pillow-packaged, or may be stored in a box, or the like. In addition, from the viewpoint of reducing moisture absorption of the solid composition, a desiccant or the like may be stored simultaneously in a packaging container such as a bottle package or a pillow package.

[0094] Materials used for SP packaging, PTP packaging, stick packaging, pillow packaging, etc. include, for example, resin films such as polypropylene film, polyethylene terephthalate film, polyethylene film, etc., and these resin films with aluminum foil attached. Either a single-layer film or a multi-layer film (for example, a laminate film) may be used.

[0095] In addition, the material constituting the packaging container preferably contains a material that is not easily affected by moisture. Examples of such packaging include packaging made of at least one of a moisture-proof material and a gas barrier material.

[0096] As the moisture-proof material, for example, a combination of PTP (polypropylene) and polyethylene aluminum pillow may be used. When the solid composition is a tablet, PTP packaging (Al-Al packaging) using aluminum on both sides may be used as the moisture-proof material, taking into consideration the suppression of increase in moisture content in the tablet, storage stability of the tablet, stability of the tablet after opening, etc.

[0097] The gas barrier material may be a known material, for example a laminate film having a functional barrier layer, which may also serve as the moisture-proof material or may be used in combination with the moisture-proof material.

[0098] Furthermore, packaging containers may be environmentally friendly, for example, environmentally friendly materials such as recycled plastics, biomass plastics, and biodegradable plastics may be used as part or all of the packaging material.

[0099] (Manufacturing method) In a second aspect, there is provided a method for producing a solid composition, comprising the steps of contacting (A) ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and salts thereof.

[0100] The solid composition can be produced using known techniques. Each component is added at any step and finally contacted with each other. A solvent or binder may be added to the contacted mixture and kneaded to obtain a kneaded product, which may be used as a solid composition. A crystal consisting of ibuprofen and tranexamic acid can be produced by the method described in JP 2022-70674 A (above). After forming a crystal consisting of ibuprofen and tranexamic acid, the crystal may be contacted or kneaded with at least one selected from the group consisting of (B) tipepidine and its salts.

[0101] The resulting mixture can be further subjected to a drying process and a granulation process to produce a granule (granulated material). In this case, the granule (granulated material) containing each component may be prepared separately. Granulation may be performed by a wet method or a dry method.

[0102] The obtained granules (granulated product) can be directly used or can be mixed with additives and compressed into tablets to produce plain tablets, or can be further film-coated.

[0103] (Property change inhibitor) In a third aspect, there is provided an agent for inhibiting property changes in a solid composition comprising (I) ibuprofen, and (II) at least one selected from the group consisting of tipepidine and its salts, which comprises at least one selected from the group consisting of tranexamic acid and its salts.

[0104] The at least one member selected from the group consisting of tranexamic acid and its salts is as described in component (C) of the solid composition of this embodiment, and the above components (I) and (II) are as described in components (A) and (B) of the solid composition of this embodiment.

[0105] The property change inhibitor is preferably used in an amount such that the amount of at least one selected from the group consisting of tranexamic acid and its salts relative to component (I) or (II) falls within the range described as the preferred content of component (C) in the solid composition according to this embodiment. In addition, tranexamic acid is preferably added to the solid composition after being crystallized with ibuprofen (in the crystallized state).

[0106] In order to explain the present invention in more detail, examples are described below, but the present invention is not limited to these. EXAMPLES

[0107] 1.Raw materials In this example, the following raw materials were used: [Table 1]

[0108] 2. Preparation of Solid Composition Comparative Example 1 50 g of tipepidine hibenzate and 50 g of ibuprofen (SI Group) were weighed out and mixed in a bag 100 times. After sieving through a 42 mesh sieve, the mixture was further mixed in a bag 100 times to obtain a physical mixed powder. 2 g of the obtained physical mixed powder was weighed out and placed in a 1K standard bottle, sealed, and adjusted to a uniform thickness to obtain a sample of Comparative Example 1.

[0109] (Example 1, Comparative Examples 2 to 4) 2.5 g of tranexamic acid (manufactured by Kyowa Pharma Chemical), tartaric acid, sodium bicarbonate, or noscapine was added to 5 g of the physically mixed powder obtained in Comparative Example 1, and the mixture was mixed in a bag 100 times. 2 g of the resulting mixture was weighed out and placed in a 1K standard bottle, which was then sealed and adjusted to have a uniform thickness, to prepare the samples of Example 1 and Comparative Examples 2 to 4.

[0110] Example 2 10 g of tipepidine hibenzate, 10 g of ibuprofen (manufactured by SI Group), and 7.6 g of tranexamic acid (manufactured by Kyowa Pharma Chemical) were weighed out and mixed in a bag 100 times. After sieving through a 42 mesh sieve, the mixture was further mixed in a bag 100 times to obtain a physical mixed powder. 2 g of the obtained physical mixed powder was weighed into a 1K standard bottle, sealed, and adjusted to a uniform thickness to obtain a sample of Example 2.

[0111] Example 3 240.0 g of ibuprofen (manufactured by Yonezawa Hamari) and 182.9 g of tranexamic acid (manufactured by AMI) were charged into a stirring mixer granulator (Vertical Granulator VG-5 (manufactured by Powrex)) and mixed to obtain a mixed powder. 69 g of a mixture of ethanol (purity 99.5%) (manufactured by Kanto Chemical) and purified water (mass ratio 8:2) was poured into this mixed powder, kneaded and granulated to obtain a kneaded product. The kneaded product was wet-disintegrated with a power mill (manufactured by Dalton) at low speed and 32 mesh. After that, it was stored in a thermostatic bath at 70°C for 89 hours to obtain crystals consisting of ibuprofen and tranexamic acid.

[0112] 6 mg of the obtained crystals were placed in an aluminum pan, and the temperature range of 25 to 350°C was measured at a rate of 60°C per minute using a differential scanning calorimeter DSC3+ (Mettler Toledo). The results are shown in Figure 1. As shown in Figure 1, the peak derived from ibuprofen at around 75°C disappeared, and a peak derived from crystals consisting of ibuprofen and tranexamic acid was observed at around 180°C, confirming that crystals with a molar ratio of ibuprofen to tranexamic acid of 1:1 were obtained.

[0113] Next, 17.6 g of the obtained crystals and 10 g of tipepidine hibenzate were weighed out and mixed in a bag 100 times. After sieving through a 42 mesh sieve, the mixture was further mixed in a bag 100 times to obtain a physical mixed powder. 2 g of the obtained physical mixed powder was weighed out and placed in a 1K standard bottle, sealed, and adjusted to a uniform thickness to obtain a sample of Example 3.

[0114] The blending ratio (mass ratio) of each sample is shown in the table below. In the table below, "IB-TXA crystal" means a crystal composed of ibuprofen and tranexamic acid. [Table 2]

[0115] 3. Evaluation of changes in properties of solid compositions Each sample of Example 1 and Comparative Examples 1 to 4 was stored under conditions of 80°C for 24 hours, and the changes in properties were evaluated. As the changes in properties, changes in state such as aggregation, solidification, moisture absorption, separation, and liquefaction were observed. The changes in state were confirmed by visual observation before and after storage to see whether aggregation, solidification, moisture absorption, separation, and liquefaction of the powder occurred.

[0116] The change in condition was then evaluated according to the following criteria. Change in condition A: No change, B: Slight change, C: Change, D: Significant change

[0117] The results of the state change compared to when the high-temperature storage was started are shown in the following table. A significant state change was observed in Comparative Examples 1 to 4. Specifically, in Comparative Examples 1, 2, and 4, a portion was liquefied and separated into two layers. In Comparative Example 3, aggregation and solidification occurred. On the other hand, the state change was suppressed in Example 1. Specifically, although aggregation and solidification occurred, the change was suppressed compared to Comparative Example 3. From the above, it was shown that the tranexamic acid added in Example 1 can suppress the property change of ibuprofen and tipepidine hibenzate under high-temperature conditions.

[0118] [Table 3]

[0119] Next, each sample of Examples 2 and 3 and Comparative Example 1 was stored under conditions of 80°C for 2 weeks to evaluate long-term property changes. As property changes, color changes and state changes such as aggregation, solidification, moisture absorption, separation, and liquefaction were observed. As for color changes, it was confirmed whether a change in color was confirmed visually before and after storage. As for state changes, it was confirmed whether aggregation, solidification, moisture absorption, separation, and liquefaction of powder occurred visually before and after storage.

[0120] Next, the color tone change and the state change were evaluated according to the following criteria. Color change A: No discoloration, B: Slight discoloration, C: Discoloration, D: Significant discoloration Change in condition A: No change, B: Slight change, C: Change, D: Significant change

[0121] The results of the color change and state change compared to when the high-temperature storage was started are shown in the following table. In Comparative Example 1, both the color change and state change were significant. Specifically, the color changed to dark brown, and a part of it became liquid and separated into two layers. In contrast, in Example 2, the state change was suppressed. Specifically, the color changed to brown and coagulation solidification occurred, but the coagulation solidification was partial. In Example 3, both the color change and state change were suppressed. Specifically, the state of white powder was maintained even after 2 weeks. From the above, it was shown that tranexamic acid can suppress the property change of ibuprofen and tipepidine hibenzate under high-temperature conditions, and the effect is particularly remarkable by forming crystals consisting of ibuprofen and tranexamic acid.

[0122] [Table 4]

[0123] Although the preferred embodiments and examples of the present invention have been described above, the present invention is not limited to these. Addition, omission, substitution, and other modifications of the configuration are possible without departing from the spirit of the present invention.

Claims

1. 1. A solid composition comprising: (A) ibuprofen, (B) at least one selected from the group consisting of tipepidine and its salts, and (C) at least one selected from the group consisting of tranexamic acid and its salts Including, A solid composition (excluding a solid composition containing levocetirizine or loratadine), wherein the mass ratio of the total amount of component (A) to component (B) is 1:1 to 16:1 ((A):(B)).

2. 2. The solid composition according to claim 1, comprising a crystal of ibuprofen and tranexamic acid.

3. 3. The solid composition of claim 2, wherein the molar ratio of ibuprofen to tranexamic acid in the crystals is 1:1.

Images